Sagimet Biosciences Inc. (SGMT)
Market: NASD |
Currency: USD
Address: 155 Bovet Road
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Show more
📈 Sagimet Biosciences Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$28.00
-
Upside/Downside from Analyst Target:
297.73%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Sagimet Biosciences Inc.
| Date | Reported EPS |
|---|
| 2025-05-08 | -0.56 |
| 2025-03-12 | -0.5 |
| 2024-11-14 | -0.45 |
| 2024-08-14 | -0.25 |
| 2024-08-13 | -0.25 |
| 2024-05-15 | -0.23 |
| 2024-05-14 | -0.23 |
| 2024-03-25 | -0.78 |
| 2024-03-24 | -0.78 |
| 2023-11-13 | -0.35 |
| 2023-11-12 | -0.35 |
| 2023-08-21 | -35.8 |
| 2023-08-20 | -35.8 |
| 2023-07-14 | - |
| 2023-07-13 | - |
📰 Related News & Research
No related articles found for "sagimet biosciences".
